A new attenuated IBR live vaccine with double genetic deletion gE-tk- is efficacious in front of experimental BoHV-1 infections, even in presence of maternally derived antibodies

Home Knowledge A new attenuated IBR live vaccine with double genetic deletion gE-tk- is efficacious in front of experimental BoHV-1 infections, even in presence of maternally derived antibodies

A new attenuated IBR live vaccine with double genetic deletion gE-tk- is efficacious in front of experimental BoHV-1 infections, even in presence of maternally derived antibodies

IBR (Infectious Bovine Rhinotracheitis) eradication programs in the EU are based mainly on a DIVA (Differentiation of Infected from Vaccinated Animals) strategy by using marker vaccines. So far, all these IBR marker vaccines were based on single deleted BoHV-1 gE- strains: Bovine HerpesVirus-1 strains lacking glycoprotein E.

About this article

Authors

Moreno, A.; Casado, C.; Roca, M.; Creixans, O.

Summary

The attenuated MLV IBR vaccine with a double genetic deletion gE-tk- (HIPRABOVIS® IBR Marker Live, HIPRA) proved to be effective, fulfilling the requirements of the monograph of the European Pharmacopeia for live vaccines against IBR.

Share this on